0.05Open0.05Pre Close0 Volume1 Open Interest7.00Strike Price0.00Turnover0.00%IV-12.28%PremiumSep 20, 2024Expiry Date0.81Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma123.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
uniQure NV Stock Discussion
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) has initiated dosing in a Phase I/IIa clinical trial of AMT-191 for Fabry diseasetreatment. The multi-center, open-label trial in the US will assess safety, tolerability, and early efficacy signs in two dose-escalating cohorts. AMT-191 is an AAV5-based gene therapy delivering a galactosidase alpha (GLA) transgene to the live...
No comment yet